Open AccessEffectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients
Author(s) -
Sabine Hazan,
Sonya Davé,
Anoja W. Gunaratne,
Sibasish Dolai,
Robert Clancy,
Peter A. McCullough,
Thomas J. Borody
Publication year - 2022
Publication title -
future microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.797
H-Index - 82
eISSN - 1746-0921
pISSN - 1746-0913
DOI - 10.2217/fmb-2022-0014
Subject(s) - medicine , ivermectin , ambulatory , doxycycline , covid-19 , hypoxia (environmental) , clinical trial , combination therapy , oxygen therapy , antibiotics , chemistry , disease , organic chemistry , oxygen , veterinary medicine , infectious disease (medical specialty) , microbiology and biotechnology , biology
Aims: Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for Helicobacter pylori , the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations. Patients & methods: In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C. Results & conclusions: All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms. Clinical Trial Registration: NCT04482686 (ClinicalTrial.gov).